VCYT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
VCYT is NOT a good buy right now for an impatient buyer. The stock is sitting right on first support (~38.10) with bearish momentum still building (MACD histogram negative and expanding) and pattern-based odds pointing to further weakness over the next week/month. While fundamentals and most analyst targets are constructive, the near-term tape does not offer a clean, high-probability entry today—this is an avoid/new-buy hold until price stabilizes and reclaims key resistance.
Price/levels: VCYT closed at ~38.09, essentially at S1=38.097 (first support). A break below S1 increases downside risk toward S2=36.157. Overhead, the key pivot/resistance zone starts around Pivot=41.237, then R1=44.377. Momentum: MACD histogram is -0.515 (below zero) and negatively expanding, which signals bearish momentum strengthening. RSI: RSI(6)=23.66 indicates the stock is oversold/washed out short-term, which can produce a bounce, but oversold alone is not a buy signal when MACD is still deteriorating. Moving averages: Converging MAs suggest the stock is in a transition phase, but without an upside cross/turn, it doesn’t confirm a reversal. Probabilistic pattern read: Similar-candlestick analogs imply ~-4.75% next week and ~-6.95% next month, reinforcing that the prevailing short-term trend bias remains down.
Intellectia Proprietary Trading Signals
on 2026-03-02 after hours (EPS est. 0.
could be a catalyst if results/guide surprise positively.
create elevated risk of a support break toward ~36.
Short-term statistical trend: Pattern-based expectation shows negative bias over 1 week and 1 month.
Latest reported quarter: 2025/Q3. Growth/profitability trends: Revenue rose to $131.872M (+13.82% YoY). Net income increased to $19.137M (+26.28% YoY) and EPS to $0.24 (+26.32% YoY), indicating improving earnings power alongside top-line growth. Gross margin improved to 68.75% (+1.96% YoY), a constructive sign for operating leverage and quality of growth.
Recent trend: Price targets have generally moved up (Guggenheim $50 from $45; UBS $48 from $42; Canaccord $43 from $40; Morgan Stanley $40 from $28), showing rising expectations overall. Pros (bull case on Wall St.): Strong execution and growth, improving margins, and supportive clinical/guideline positioning for Decipher. Cons (bear case on Wall St.): At least one major firm remains Underweight (Morgan Stanley), and some analysts (e.g., Canaccord) are waiting for clearer visibility into durable long-term growth drivers. Influential/political trading: No recent congress trading data available; hedge fund and insider activity reported as neutral with no significant recent trends.
